Genfit (GNFT)

• Market cap: $183M
• 1 day: -2.67%
• 5 days: -3.44%
• 1 month: -13.10%
• 3 months: 7.67%
• 6 months: 6.10%
• Year to date: -4.70%
• 1 year: -17.05%
• 5 years: -31.78%
• 10 years: -83.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Employees: 180

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

33% more funds holding

Funds holding: 6 [Q4 2024] → 8 (+2) [Q1 2025]

0.01% more ownership

Funds ownership: 0.41% [Q4 2024] → 0.42% (+0.01%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

2% less capital invested

Capital invested by funds: $755K [Q4 2024] → $740K (-$15.3K) [Q1 2025]